Sonnet Historical Income Statement

SONN Stock

USD 1.62 0.02 1.22%

Historical analysis of Sonnet Biotherapeutics income statement accounts such as Gross Profit of 34.3 M, Other Operating Expenses of 4.5 M, Total Operating Expenses of 4.5 M or Cost Of Revenue of 11.8 M can show how well Sonnet Biotherapeutics Holdings performed in making a profits. Evaluating Sonnet Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Sonnet Biotherapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Sonnet Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sonnet Biotherapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Sonnet Income Statement Analysis

Sonnet Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Sonnet Biotherapeutics shareholders. The income statement also shows Sonnet investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Sonnet Biotherapeutics Income Statement Chart

At this time, Sonnet Biotherapeutics' Interest Income is very stable compared to the past year.

Selling General Administrative Total Revenue Other Operating Expenses Cost Of Revenue

Total Revenue

Total revenue comprises all receipts Sonnet Biotherapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Sonnet Biotherapeutics. It is also known as Sonnet Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Sonnet Biotherapeutics income statement and represents the costs associated with goods and services Sonnet Biotherapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Sonnet Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Sonnet Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Sonnet Biotherapeutics' Interest Income is very stable compared to the past year.

	2024	2025 (projected)
Non Recurring	10.9M	11.5M
Cost Of Revenue	7.1M	11.8M

Non Recurring Cost Of Revenue

Sonnet Biotherapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Discontinued Operations	Net Income From Continuing Ops	Cost Of Revenue	Non Recurring	Non Operating Income Net Other	Income Tax Expense	Minority Interest	Tax Provision	Interest Income	Extraordinary Items	Selling And Marketing Expenses	Net Interest Income	Research Development
Depreciation And Amortization		0.33	-0.01	0.72	0.63	0.42	0.42	0.43	0.48	0.03	0.38	-0.17	0.39	0.03	0.42	0.16	-0.19	0.03	-0.5	-0.35	-0.22	0.44	-0.18	-0.12	-0.47	-0.56
Interest Expense	0.33		-0.17	0.53	0.15	-0.01	0.16	0.14	0.12	-0.14	0.06	-0.36	0.12	0.18	-0.07	0.59	0.43	-0.26	-0.12	-0.46	-0.3	0.5	0.46	0.53	-0.44	-0.22
Selling General Administrative	-0.01	-0.17		-0.28	-0.15	0.36	-0.82	-0.8	-0.79	0.65	-0.76	0.36	-0.78	-0.54	-0.53	-0.24	0.35	-0.11	0.18	-0.28	0.08	-0.42	-0.02	-0.01	0.6	0.67
Total Revenue	0.72	0.53	-0.28		0.75	0.21	0.5	0.4	0.54	-0.21	0.36	-0.51	0.4	0.21	0.13	0.37	0.02	-0.09	-0.37	-0.32	-0.32	0.54	-0.03	0.13	-0.49	-0.58
Gross Profit	0.63	0.15	-0.15	0.75		-0.16	0.42	0.37	0.47	-0.17	0.46	0.08	0.44	-0.2	0.1	-0.33	0.04	0.26	0.08	-0.03	0.2	0.07	-0.22	-0.21	-0.48	-0.51
Other Operating Expenses	0.42	-0.01	0.36	0.21	-0.16		-0.18	-0.21	-0.11	0.31	-0.36	-0.54	-0.33	0.27	0.11	0.47	-0.34	-0.19	-0.81	-0.37	-0.49	0.45	-0.12	-0.02	0.24	0.07
Operating Income	0.42	0.16	-0.82	0.5	0.42	-0.18		0.97	0.99	-0.65	0.96	-0.3	0.97	0.53	0.8	0.18	-0.55	0.1	-0.32	0.34	-0.22	0.56	-0.4	-0.3	-0.84	-0.96
Ebit	0.43	0.14	-0.8	0.4	0.37	-0.21	0.97		0.97	-0.61	0.97	-0.14	0.98	0.42	0.83	0.14	-0.49	0.04	-0.26	0.27	-0.2	0.46	-0.33	-0.22	-0.84	-0.91
Ebitda	0.48	0.12	-0.79	0.54	0.47	-0.11	0.99	0.97		-0.58	0.95	-0.29	0.95	0.46	0.79	0.17	-0.54	0.07	-0.36	0.25	-0.24	0.52	-0.38	-0.26	-0.82	-0.94
Total Operating Expenses	0.03	-0.14	0.65	-0.21	-0.17	0.31	-0.65	-0.61	-0.58		-0.62	0.21	-0.65	-0.59	-0.51	-0.15	0.34	-0.05	-0.08	-0.58	0.12	-0.36	0.23	0.18	0.56	0.62
Income Before Tax	0.38	0.06	-0.76	0.36	0.46	-0.36	0.96	0.97	0.95	-0.62		-0.01	1.0	0.33	0.79	-0.04	-0.47	0.16	-0.1	0.39	-0.05	0.34	-0.41	-0.34	-0.85	-0.91
Total Other Income Expense Net	-0.17	-0.36	0.36	-0.51	0.08	-0.54	-0.3	-0.14	-0.29	0.21	-0.01		-0.08	-0.76	-0.16	-0.79	0.34	0.18	0.75	0.11	0.59	-0.81	0.01	-0.12	0.13	0.31
Net Income	0.39	0.12	-0.78	0.4	0.44	-0.33	0.97	0.98	0.95	-0.65	1.0	-0.08		0.4	0.8	0.02	-0.48	0.16	-0.14	0.4	-0.09	0.42	-0.4	-0.34	-0.86	-0.93
Discontinued Operations	0.03	0.18	-0.54	0.21	-0.2	0.27	0.53	0.42	0.46	-0.59	0.33	-0.76	0.4		0.57	0.59	-0.66	0.04	-0.58	0.44	-0.47	0.85	-0.32	-0.26	-0.32	-0.55
Net Income From Continuing Ops	0.42	-0.07	-0.53	0.13	0.1	0.11	0.8	0.83	0.79	-0.51	0.79	-0.16	0.8	0.57		0.11	-0.81	0.21	-0.48	0.45	-0.2	0.57	-0.58	-0.55	-0.69	-0.83
Cost Of Revenue	0.16	0.59	-0.24	0.37	-0.33	0.47	0.18	0.14	0.17	-0.15	-0.04	-0.79	0.02	0.59	0.11		-0.02	-0.51	-0.61	-0.38	-0.75	0.7	0.27	0.48	-0.1	-0.17
Non Recurring	-0.19	0.43	0.35	0.02	0.04	-0.34	-0.55	-0.49	-0.54	0.34	-0.47	0.34	-0.48	-0.66	-0.81	-0.02		-0.33	0.59	-0.61	0.16	-0.52	0.74	0.76	0.3	0.59
Non Operating Income Net Other	0.03	-0.26	-0.11	-0.09	0.26	-0.19	0.1	0.04	0.07	-0.05	0.16	0.18	0.16	0.04	0.21	-0.51	-0.33		0.04	0.43	0.81	0.02	-0.14	-0.61	-0.13	-0.23
Income Tax Expense	-0.5	-0.12	0.18	-0.37	0.08	-0.81	-0.32	-0.26	-0.36	-0.08	-0.1	0.75	-0.14	-0.58	-0.48	-0.61	0.59	0.04		0.22	0.51	-0.76	0.18	0.11	0.16	0.37
Minority Interest	-0.35	-0.46	-0.28	-0.32	-0.03	-0.37	0.34	0.27	0.25	-0.58	0.39	0.11	0.4	0.44	0.45	-0.38	-0.61	0.43	0.22		0.23	0.06	-0.67	-0.77	-0.2	-0.35
Tax Provision	-0.22	-0.3	0.08	-0.32	0.2	-0.49	-0.22	-0.2	-0.24	0.12	-0.05	0.59	-0.09	-0.47	-0.2	-0.75	0.16	0.81	0.51	0.23		-0.52	0.18	-0.27	0.1	0.17
Interest Income	0.44	0.5	-0.42	0.54	0.07	0.45	0.56	0.46	0.52	-0.36	0.34	-0.81	0.42	0.85	0.57	0.7	-0.52	0.02	-0.76	0.06	-0.52		-0.22	-0.15	-0.5	-0.66
Extraordinary Items	-0.18	0.46	-0.02	-0.03	-0.22	-0.12	-0.4	-0.33	-0.38	0.23	-0.41	0.01	-0.4	-0.32	-0.58	0.27	0.74	-0.14	0.18	-0.67	0.18	-0.22		0.86	0.27	0.48
Selling And Marketing Expenses	-0.12	0.53	-0.01	0.13	-0.21	-0.02	-0.3	-0.22	-0.26	0.18	-0.34	-0.12	-0.34	-0.26	-0.55	0.48	0.76	-0.61	0.11	-0.77	-0.27	-0.15	0.86		0.21	0.42
Net Interest Income	-0.47	-0.44	0.6	-0.49	-0.48	0.24	-0.84	-0.84	-0.82	0.56	-0.85	0.13	-0.86	-0.32	-0.69	-0.1	0.3	-0.13	0.16	-0.2	0.1	-0.5	0.27	0.21		0.87
Research Development	-0.56	-0.22	0.67	-0.58	-0.51	0.07	-0.96	-0.91	-0.94	0.62	-0.91	0.31	-0.93	-0.55	-0.83	-0.17	0.59	-0.23	0.37	-0.35	0.17	-0.66	0.48	0.42	0.87

Click cells to compare fundamentals

Sonnet Biotherapeutics Account Relationship Matchups

Sonnet Biotherapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	2.2M	95.2K	93.3K	75.8K	1.9M	1.0M
Selling General Administrative	2.5M	8.9M	8.6M	7.1M	6.1M	2.4M
Total Revenue	40.6M	483.6K	349.9K	147.8K	18.6K	42.6M
Gross Profit	32.7M	(16.2M)	256.7K	(11.7M)	18.6K	34.3M
Other Operating Expenses	4.7M	25.6M	30.0M	18.9M	11.9M	4.5M
Operating Income	(4.7M)	(25.1M)	(29.7M)	(18.8M)	(11.8M)	(4.9M)
Ebit	(4.7M)	(25.1M)	(29.7M)	(18.8M)	(4.2M)	(4.4M)
Ebitda	(2.5M)	(25.0M)	(29.6M)	(18.7M)	(11.8M)	(2.7M)
Total Operating Expenses	4.7M	25.6M	30.0M	18.9M	11.9M	4.5M
Income Before Tax	(4.9M)	(25.0M)	(29.7M)	(18.8M)	(7.4M)	(5.1M)
Total Other Income Expense Net	(162.9K)	103.5K	(52.5K)	(40.1K)	4.4M	(171.0K)
Net Income	(5.0M)	(25.0M)	(29.8M)	(18.8M)	(7.4M)	(5.3M)
Net Income From Continuing Ops	(17.4M)	(25.0M)	(29.7M)	(18.8M)	(7.4M)	(18.3M)
Cost Of Revenue	7.9M	16.6M	93.3K	11.8M	7.1M	11.8M
Income Tax Expense	162.9K	22.0K	52.5K	40.1K	187.3K	177.9K
Research Development	2.2M	16.6M	21.4M	11.8M	5.7M	2.1M

When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:

How To Invest In Sonnet

Details

Is Sonnet Stock a good investment?

Details

What is Sonnet Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.35)

Revenue Per Share

0.019

Quarterly Revenue Growth

(0.50)

Return On Assets

(0.97)

Return On Equity

(2.65)

The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sonnet Historical Income Statement

About Sonnet Income Statement Analysis

Sonnet Biotherapeutics Income Statement Chart

Total Revenue

Other Operating Expenses

Cost Of Revenue

Sonnet Biotherapeutics income statement Correlations

Sonnet Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sonnet Biotherapeutics income statement Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income	+ 1.0	Income Before Tax
Ebitda	+ 0.99	Operating Income
Net Income	+ 0.98	Ebit
Ebit	+ 0.97	Operating Income
Net Income	+ 0.97	Operating Income
Ebitda	+ 0.97	Ebit

Research Development	- 0.96	Operating Income
Research Development	- 0.94	Ebitda
Research Development	- 0.93	Net Income
Research Development	- 0.91	Income Before Tax
Research Development	- 0.91	Ebit
Net Interest Income	- 0.86	Net Income